Viridian Therapeutics Stock Performance
| VRDN Stock | USD 24.21 1.20 5.22% |
On a scale of 0 to 100, Viridian Therapeutics holds a performance score of 15. The entity has a beta of -0.43, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Viridian Therapeutics are expected to decrease at a much lower rate. During the bear market, Viridian Therapeutics is likely to outperform the market. Please check Viridian Therapeutics' downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to make a quick decision on whether Viridian Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Viridian Therapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Viridian Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 102.8 M | |
| Total Cashflows From Investing Activities | -228.7 M |
Viridian Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,679 in Viridian Therapeutics on July 20, 2025 and sell it today you would earn a total of 742.00 from holding Viridian Therapeutics or generate 44.19% return on investment over 90 days. Viridian Therapeutics is currently generating 0.6135% in daily expected returns and assumes 3.1743% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Viridian, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Viridian Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viridian Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Viridian Therapeutics, and traders can use it to determine the average amount a Viridian Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1933
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VRDN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.17 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.61 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 15 85% of assets perform better |
Based on monthly moving average Viridian Therapeutics is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viridian Therapeutics by adding it to a well-diversified portfolio.
Viridian Therapeutics Fundamentals Growth
Viridian Stock prices reflect investors' perceptions of the future prospects and financial health of Viridian Therapeutics, and Viridian Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Viridian Stock performance.
| Return On Equity | -0.66 | |||
| Return On Asset | -0.4 | |||
| Current Valuation | 1.38 B | |||
| Shares Outstanding | 81.66 M | |||
| Price To Book | 5.31 X | |||
| Price To Sales | 6,482 X | |||
| Revenue | 302 K | |||
| EBITDA | (265.66 M) | |||
| Cash And Equivalents | 161.21 M | |||
| Cash Per Share | 5.66 X | |||
| Total Debt | 21.09 M | |||
| Debt To Equity | 0.04 % | |||
| Book Value Per Share | 4.00 X | |||
| Cash Flow From Operations | (232.32 M) | |||
| Earnings Per Share | (3.57) X | |||
| Total Asset | 742.4 M | |||
| Retained Earnings | (995.86 M) | |||
About Viridian Therapeutics Performance
By examining Viridian Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Viridian Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Viridian Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts. Viridian Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people.Things to note about Viridian Therapeutics performance evaluation
Checking the ongoing alerts about Viridian Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Viridian Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Viridian Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 302 K. Net Loss for the year was (269.95 M) with loss before overhead, payroll, taxes, and interest of (304.27 M). | |
| Viridian Therapeutics currently holds about 161.21 M in cash with (232.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66. | |
| Over 100.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Viridian Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Viridian Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Viridian Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Viridian Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Viridian Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Viridian Therapeutics' stock. These opinions can provide insight into Viridian Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.